Darling Ingredients Inc. Common Stock vs Heron Therapeutics Inc — how do they compare? Darling Ingredients Inc. Common Stock trades at $62.14 (market cap $9.47B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Darling Ingredients Inc. Common Stock is far larger — about 127.9× Heron Therapeutics Inc's market cap, and Darling Ingredients Inc. Common Stock is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Darling Ingredients Inc. Common Stock for 0 Days and Heron Therapeutics Inc for 35 Days on average.
| DAR | HRTX | |
|---|---|---|
Market Cap | $9.47B | $74.04M |
Volume | 1,505,770 | 3,668,095 |
Sector | Consumer Staples | Health |
52-Week High | $68.34 | $1.49 |
52-Week Low | $29.91 | $0.27 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $13.48B | $180.78M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Darling Ingredients collects and processes used cooking oil, animal by-products, and food waste. It produces ingredients and renewable fuel feedstocks from these materials.
Read more on DAR →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →